CRVS Stock Summary and Trading Ideas (Corvus Pharmaceuticals | NASDAQ:CRVS)

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Corvus Pharmaceuticals trades on the NASDAQ stock market under the symbol CRVS.

As of December 5, 2025, CRVS stock price was flat at $8.81 with 1,195,781 million shares trading.

CRVS has a beta of 1.16, meaning it tends to be more sensitive to market movements. CRVS has a correlation of 0.06 to the broad based SPY ETF.

CRVS has a market cap of $657.95 million. This is considered a Small Cap stock.

In the last 3 years, CRVS traded as high as $10.00 and as low as $.61.

The top ETF exchange traded funds that CRVS belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.

CRVS has underperformed the market in the last year with a price return of +8.4% while the SPY ETF gained +14.2%. However, in the short term, CRVS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +43.0% vs +6.2% return in SPY. But in the last 2 weeks, CRVS shares have been beat by the market, returning +2.8% compared to an SPY return of +4.0%.

CRVS support price is $8.40 and resistance is $9.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRVS shares will trade within this expected range on the day.